|
ИСТИНА |
Войти в систему Регистрация |
Интеллектуальная Система Тематического Исследования НАукометрических данных |
||
Circulating 25-hydroxyvitamin D3 and survival after diagnosis with kidney cancerстатья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или ScopusДата последнего поиска статьи во внешних источниках: 4 марта 2022 г.
- Авторы: Muller D.C., Scelo G., Zaridze D., Janout V., Holcatova I., Navratilova M., Mates D., Midttun Ø., Ueland P.M., Brennan P., Johansson M.
- Журнал: Cancer Epidemiology Biomarkers and Prevention
- Том: 24
- Номер: 8
- Год издания: 2015
- Издательство: American Association for Cancer Research
- Местоположение издательства: United States
- Первая страница: 1277
- Последняя страница: 1281
- DOI: 10.1158/1055-9965.EPI-14-1351.
- Аннотация: Prospective cohort studies have provided some evidence that circulating vitamin D is associated with risk of, and survival from, renal cell carcinoma (RCC), but it is unclear whether concentrations of vitamin D at the time of diagnosis of RCC are associated with prognosis. We conducted a case-cohort study of 630 RCC cases, including 203 deaths, from a multicenter case-control study in Eastern Europe. Vitamin D was assessed as 25-hydroxyvitamin D3 [25(OH)D3], and we used weighted Cox models to estimate hazard ratios (HR) and 95% confidence intervals (CI) by categories of season-adjusted 25(OH)D3. Higher concentrations of 25(OH)D3 were associated with lower risk of death after adjusting for stage, age, sex, and country (HR highest vs. lowest category 0.57; 95% CI, 0.34-0.97). The inverse associations of 25(OH)D3 with death were most notable among those who died from non-RCC causes and those diagnosed with early-stage disease. In summary, 25(OH)D3 concentration at diagnosis of RCC was inversely associated with all-cause mortality rates, but not specifically with RCC outcome.
- Добавил в систему: Заридзе Давид Георгиевич